Leukemic stem cell subtypes determine venetoclax resistance and therapeutic vulnerabilities in AML
Cell Stem Cell · 2026-06 · 33 (6) · 982-999.e8
DOI: 10.1016/j.stem.2026.04.012 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cell Stem Cell, 2026-06. Verfasst von Alexander Waclawiczek und 29 weiteren Autor:innen. Beteiligte Einrichtung: Division of Stem Cells and Cancer, German Cancer Research Center (DKFZ) and DKFZ-ZMBH Alliance, Heidelberg, Germany; Heidelberg Institute for Stem Ce…. Hauptthemen laut MEDLINE: Bridged Bicyclo Compounds, Heterocyclic, Sulfonamides, Leukemia, Myeloid, Acute, Neoplastic Stem Cells. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 64 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: European Research Council, Horizon Europe, Bundesministerium für Forschung, Technologie und Raumfahrt.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Stem Cells and Cancer, German Cancer Research Center (DKFZ) and DKFZ-ZMBH Alliance, Heidelberg, Germany; Heidelberg Institute for Stem Cell Technology and Experimental Medicine (HI-STEM gGmbH), Heidelberg, G…
- Faculty of Biosciences, Heidelberg University, Heidelberg, Germany; National Center for Tumor Diseases (NCT) Heidelberg, Heidelberg, Germany.
- Department of Internal Medicine V, Hematology, Oncology and Rheumatology, Heidelberg University Hospital, Heidelberg, Germany.
- Max Planck Institute of Immunobiology and Epigenetics, Freiburg, Germany.
- Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland.
- German Cancer Consortium (DKTK), Heidelberg, Germany.
Förderung
- European Research Council
- Horizon Europe
- Bundesministerium für Forschung, Technologie und Raumfahrt
- German Cancer Aid
- Horizon 2020 Framework Programme
- EMBO
- Joachim Herz Stiftung
- Deutsches Krebsforschungszentrum
Zitieren
APA
Waclawiczek, A., Leppä, A. M., Renders, S., Bergerweiss, I., Stumpf, K., Betz, B., Gabrowski, S., Huang, F. Y., Lalioti, M. E., Hempel, B., Sohn, M., Kuusanmäki, H., Thiel, V., Unglaub, J. M., Shahswar, R., Richter, S., Janssen, M., Karpova, D., Donato, E., …, & Trumpp, A. (2026). Leukemic stem cell subtypes determine venetoclax resistance and therapeutic vulnerabilities in AML. Cell Stem Cell, 33(6), 982-999.e8. https://doi.org/10.1016/j.stem.2026.04.012
Vancouver
Waclawiczek A, Leppä AM, Renders S, Bergerweiss I, Stumpf K, Betz B, et al. Leukemic stem cell subtypes determine venetoclax resistance and therapeutic vulnerabilities in AML. Cell Stem Cell. 2026;33(6):982-999.e8. doi:10.1016/j.stem.2026.04.012
BibTeX
@article{Waclawiczek2026,
author = {Waclawiczek, Alexander and Leppä, Aino-Maija and Renders, Simon and Bergerweiss, Ines and Stumpf, Karolin and Betz, Barbara and Gabrowski, Susanna and Huang, Frank Y and Lalioti, Maria-Eleni and Hempel, Bendix and Sohn, Markus and Kuusanmäki, Heikki and Thiel, Vera and Unglaub, Julia M and Shahswar, Rabia and Richter, Sarah and Janssen, Maike and Karpova, Darja and Donato, Elisa and Bonig, Halvard and Röllig, Christoph and Raffel, Simon and Heuser, Michael and Hundemer, Michael and Kontro, Mika and Eisfeld, Ann-Kathrin and Sauer, Tim and Cabezas-Wallscheid, Nina and Müller-Tidow, Carsten and Trumpp, Andreas},
title = {Leukemic stem cell subtypes determine venetoclax resistance and therapeutic vulnerabilities in AML},
journal = {Cell Stem Cell},
year = {2026},
volume = {33},
number = {6},
pages = {982--999.e8},
doi = {10.1016/j.stem.2026.04.012}
}
EUVIMED